PRNewsWire
17 Jul 2026, 13:00 UTC · 17w ago
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
Impact · against what's priced in
IDEAYA and Hengrui Pharma receive positive catalysts from the announcement of upcoming ESMO 2026 data presentations and the targeting of a registrational trial for IDE849 by year-end 2026. The move toward pivotal trials for the DLL3 ADC represents a significant de-risking milestone for both partners.
- IDYA+0.60
No priced-in read yet





